Wondfo Biology Co., Ltd., and Shenzhen Tisenc Medical Device Co., Ltd., a domestic chemiluminescence enterprise, have signed an agreement to acquire 100% equity and corresponding interests of Tisenc medical. After the completion of the transaction, Tisenc Medical will become a wholly-owned subsidiary of Wondfo.

Through this acquisition, Wondfo aims to expand its innovative layout in the field of chemiluminescence and further enhance the chemiluminescence product line and revenue scale. At the same time, with the help of Wondfo' s global sales channels and marketing network, Tisenc can promote its medical products to cover the multi-dimensional market faster, so as to achieve the effect of "1 + 1 > 2".

Globally, IVD has a broad market space. According to the data of Cinda securities, at present, the total global market of IVD is close to US $80 billion, of which the market share of immunodiagnostic products is the highest, nearly one-third of the total, while chemiluminescence is still the track with the largest total market volume and the highest profit margin. According to the analysis of Huachuang Securities, the localization rate of chemiluminescence in China at this stage is only 20% - 25%, and there is a wide space for import substitution.

Wondfo announced that the acquisition conforms to the development trend of the market, helps to promote the healthy and steady development of Tisenc Medical business, and will further consolidate Wondfo` s competitive advantage and industry position in the industry.

About Wondfo:

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.

Based on the above technology platforms, Wondfo has extended the product lines to the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, etc. The company` s products are widely used in the rapid diagnosis and effective treatment monitoring of critical and severe diseases, chronic disease management, maternal and children healthcare, blood glucose monitoring, drug detection, alcohol testing, forensic expertise and other fields.

In recent years, Wondfo has built a global " Wondfo Ecosystem" and expanded the global coverage of products, technologies and channels by setting joint innovation bases, joint operation centers, and cross-border mergers and acquisitions. To integrate global research and innovation resources, Wondfo has established research and development centers in San Diego, and Guangzhou, and introduced more than 530 top-notch researchers at home and abroad. Besides, Wondfo invested in factories in Asia, South America, Africa and the commonwealth of independent states to build a global manufacturing system that helps reduce the delivery time and cost.

As customer satisfaction to be their priority, Wondfo continues to expand the global service network to more efficiently serve customers  all over the world. Wondfo has set up more than 20 subsidiaries worldwide, providing products, solutions, and technical support to customers in more than 140 regions and countries.

The Flu Series is the star product of Wondfo which keeps brilliant records. It is the only product in China obtaining the registration certificate for antigen detection of H7 subtype avian influenza virus. And it is the only influenza detection product in China with a full range of test menu (H7, FIuA, FIuB, FIuA&B). In recent years, Wondfo launched a molecular diagnostic technology platform for more accurate diagnosis of influenza diseases, infectious diseases, and tumor concomitant.

The booth No. of Wondfo on 2022 CACLP (Mar. 27th-29th) is A4-0501.

About Tisenc:

Founded in 2015, Shenzhen Tisenc Medical Devices Co., Ltd. is a Sino-foreign joint venture. Located in Shenzhen, China. The Company manufactures and sells both instruments and reagents. Its small size, MINI (POCT) CLIA analyzers and All-In-One Single Does reagent Strip, named ACCRE, allow for performing hundreds of assays, especially Cardiac markers, Thyroid, Hormones, Inflammation, Anemia, Infection disease... 

The Company offers a complete and interesting list of products for various target customers, from small laboratories to middle size diagnostic centers. Tisenc has owned ISO13485, CE certificate, Europe FSC and Chinese FDA approved.